UP-TO-DATE, RESEARCH BASED INFORMATION ABOUT PSYCHEDELICS.
Drug-drug interactions between classic psychedelics and psychoactive drugs: a systematic review
These studies provide insights into the interactions between classic psychedelics and a range of drugs, including antidepressants, antipsychotics, anxiolytics, mood stabilisers, recreational drugs and others.
Extrapharmacological safety topics in psychedelic-assisted psychotherapy
The increasing popularity of psychedelic-assisted psychotherapy (PAP) has generated important discussions about the safety of psychedelic drugs.
Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants
The results indicate that any differences in the pharmacological profiles of mescaline, LSD, and psilocybin do not translate into relevant differences in the subjective experience.
Phenomenology and therapeutic potential of patient experiences during oral esketamine treatment for treatment-resistant depression: an interpretative phenomenological study
Patients reported several esketamine effects with psychotherapeutic potential, such as increased openness, detachment, an interruption of negativity, and mystical-type experiences.
Changed substance use after psychedelic experiences among individuals in Canada
Participants reported substantial changes, with 43.8% (n = 651/1488) decreasing or ceasing alcohol use, 42.5% (n = 272/640) ceasing or decreasing antidepressant use, and 42.4% (n = 200/471) decreasing or ceasing cocaine use.
Ketamine versus ECT for nonpsychotic treatment-resistant major depression
Ketamine was noninferior to ECT as therapy for treatment-resistant major depression without psychosis.
Applying key lessons from the hospice and palliative care movement to inform psychedelic-assisted therapy
The intention of this commentary is to articulate the deep synergies between hospice and palliative care and PAT.
Exposure therapy under psilocybin for general anxiety disorder and claustrophobia
The protocol included both an imaginary exposure exercise and a classic exposure therapy in an elevator during the psilocybin-assisted psychotherapy.
One-year outcomes following intravenous ketamine plus digital training among patients with treatment-resistant depression: A secondary analysis of a randomized clinical trial
Our study found that the rapid effects of ketamine can be made more enduring with simple, portable, digital techniques.
Psychedelics as transformative therapeutics
This review covers the latest advances ... utilizing this class of compounds as emerging therapeutics.
Dose-response relationships of LSD-induced subjective experiences in humans
Most scales revealed a sigmoid-like increase of effects, with a plateauing at around 100 μg.
Oregon approves first psilocybin service centre - single high doses session to cost $3,500
Late last week, Oregon Health Authority announced that it has issued the first psilocybin service centre licence.
The top 5 psychedelic clinical trials of 2022
Psychedelic Alpha’s Medical Advisor, Michael Haichin, nominates what he felt were the five most impressive psychedelic clinical trials of 2022.
Dosing and therapeutic conduct in administration sessions in substance-assisted psychotherapy: A systematized review
Essential components of therapeutic interventions remain largely tentative, necessitating systematic investigation.
The varieties of 'psychedelic decriminalization'
The words “psychedelic decriminalization” on their own tell us very little about what a given policy proposal would actually do, and there are often very significant and consequential differences between particular policies.
